| 1 |
21178300 | Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. | 2011 |
1 |
| 2 |
21511944 | In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. | 2011 Jul |
2 |
| 3 |
20214592 | Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. | 2009 Nov |
1 |
| 4 |
18413310 | Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. | 2008 Jun 20 |
1 |
| 5 |
17201456 | Pharmacokinetic interactions with thiazolidinediones. | 2007 |
1 |
| 6 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
1 |
| 7 |
12642470 | Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. | 2003 Apr |
1 |
| 8 |
11921435 | Differentiating members of the thiazolidinedione class: a focus on safety. | 2002 Mar-Apr |
2 |
| 9 |
10659951 | In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. | 2000 Jan |
2 |
| 10 |
10534310 | Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. | 1999 Nov |
2 |